Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life

• Status: Unknown status
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Criteria

Inclusion Criteria:

• Patient with histologically proven tumor with bone metastasis, single or multiple (with or without metastasis extra-osseous)

• Patients treated with injectable bone antiresorptive therapy for 12 months or more

• Signed written informed consent

Exclusion Criteria:

• patient with any medical or psychiatric condition or disease which would make the patient inappropriate to complete quality of life questionaries

• patient under guardianship, curator or under the protection of justice, pregnant or breast-feeding women